Kymera Therapeutics Inc (NASDAQ: KYMR) on Tuesday, plunged -4.07% from the previous trading day, before settling in for the closing price of $36.81. Within the past 52 weeks, KYMR’s price has moved between $29.24 and $53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 301.53%. The company achieved an average annual earnings per share of -11.95%. With a float of $53.91 million, this company’s outstanding shares have now reached $64.75 million.
Let’s determine the extent of company efficiency that accounts for 187 employees. In terms of profitability, gross margin is 92.85%, operating margin of -223.0%, and the pretax margin is -191.26%.
Kymera Therapeutics Inc (KYMR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 16.76%, while institutional ownership is 95.18%. The most recent insider transaction that took place on Jan 06 ’25, was worth 130,645. In this transaction Chief Legal Officer of this company sold 3,129 shares at a rate of $41.75, taking the stock ownership to the 54,826 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Officer proposed sale 3,129 for $41.59, making the entire transaction worth $130,135.
Kymera Therapeutics Inc (KYMR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.97% during the next five years compared to -39.18% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 8.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Looking closely at Kymera Therapeutics Inc (NASDAQ: KYMR), its last 5-days average volume was 0.43 million, which is a drop from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 53.67%. Additionally, its Average True Range was 2.10.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 9.13%, which indicates a significant decrease from 28.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.33% in the past 14 days, which was lower than the 55.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.98, while its 200-day Moving Average is $41.73. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $36.92. Second resistance stands at $38.53. The third major resistance level sits at $39.43. If the price goes on to break the first support level at $34.41, it is likely to go to the next support level at $33.51. Should the price break the second support level, the third support level stands at $31.90.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
Market capitalization of the company is 2.29 billion based on 64,765K outstanding shares. Right now, sales total 78,590 K and income totals -146,960 K. The company made 3,740 K in profit during its latest quarter, and -62,490 K in sales during its previous quarter.
